Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate

Journal of Virology

Volumn 89, Issue 18, 2015, Pages 9499-9510

  Liang, Bo ^a   Surman, Sonja ^a   Amaro Carambot, Emerito ^a   Kabatova, Barbora ^a   Mackow, Natalie ^a   Lingemann, Matthias ^a   Yang, Lijuan ^a   McLellan, Jason S ^a,b   Graham, Barney S ^a   Kwong, Peter D ^a   Schaap Nutt, Anne ^a   Collins, Peter L ^a   Munir, Shirin ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOPROTEIN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; PHOSPHOPROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS FUSION PROTEIN; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BRONCHIOLITIS; CELL CULTURE; CLINICAL EVALUATION; CODON; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC STABILITY; HAMSTER; HUMAN PARAINFLUENZA VIRUS 3; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGENICITY; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS NEUTRALIZATION; ANIMAL; BIOSYNTHESIS; CHLOROCEBUS AETHIOPS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VERO CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CRICETINAE; GENE EXPRESSION; HUMANS; PARAINFLUENZA VIRUS 3, HUMAN; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VERO CELLS; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 84940554676     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01373-15     Document Type: Article

References (42)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Ottolini MG, Porter DD, Hemming VG, Prince GA. 2000. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol 13:231- 236. http://dx.doi.org/10.1089/vim.2000.13.231.
3. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
4. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484. http://dx.doi.org/10.1016/0264-410X(92)90397-3.
5. Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E. 2004. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 189:462-470. http://dx.doi .org/10.1086/381184.
6. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR. 2007. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25:7372-7378. http://dx.doi.org/10.1016/j.vaccine.2007.08.014.
7. Bernstein D, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. 2012. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 31:109-114. http://dx.doi.org/10.1097 /INF.0b013e31823386f1.
8. Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH. 2000. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74:8922-8929. http://dx.doi.org/10.1128/JVI .74.19.8922-8929.2000.
9. Yang C-F, Wang CK, Malkin E, Schickli JH, Shambaugh C, Zuo F, Galinski MS, Dubovsky F, Tang RS. 2013. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 31:2822-2827. http://dx.doi.org/10.1016/j .vaccine.2013.04.006.
10. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131. http://dx.doi.org/10.1006/viro .2000.0279.
11. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
12. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http: //dx.doi.org/10.1128/JVI.00555-11.
13. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
14. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44. http://dx.doi.org/10.1038/nature04322.
15. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR. 1999. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 73:2956-2962.
16. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089- 3094. http://dx.doi.org/10.1073/pnas.1115941109.
17. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx.doi .org/10.1126/science.1243283.
18. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72:4467-4471.
19. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2013. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 87: 1985-1996. http://dx.doi.org/10.1128/JVI.02769-12.
20. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of theM2mRNAin gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 92:11563-11567. http://dx.doi.org/10.1073/pnas.92 .25.11563.
21. Hall SL, Stokes A, Tierney EL, London WT, Belshe RB, Newman FC, Murphy BR. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 22:173-184. http://dx.doi.org/10.1016/0168-1702(92)90049-F.
22. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. 2001. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75:4594-4603. http://dx.doi.org/10.1128/JVI.75.10.4594-4603.2001.
23. Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A. 2014. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. J Virol 88: 4237-4250. http://dx.doi.org/10.1128/JVI.03481-13.
24. Calain P, Roux L. 1993. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67:4822- 4830.
25. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. 1998. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 72:891-899.
26. Buchholz UJ, Finke S, Conzelmann K-K. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73:251-259.
27. Beeler JA, van Wyke Coelingh K. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:2941-2950.
28. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA. 2004. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78:11198-11207. http://dx.doi.org/10.1128/JVI.78.20.11198 -11207.2004.
29. van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR. 1988. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 157:655-662. http://dx.doi.org/10.1093/infdis/157.4 .655.
30. Coates HV, Alling DW, Chanock RM. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 83:299-313.
31. Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR. 1999. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J Infect Dis 179: 1345-1351. http://dx.doi.org/10.1086/314769.
32. Coates HV, Forsyth BR, Chanock RM. 1966. Biophysical studies of respiratory syncytial virus. I. Density of respiratory syncytial virus and associated complement-fixing antigens in cesium chloride density gradient. J Bacteriol 91:1263-1269.
33. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2012. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 86:10792-10804. http://dx.doi.org/10.1128/JVI.01227-12.
34. Yoder SM, Zhu Y, Ikizler MR, Wright PF. 2004. Role of complement in neutralization of respiratory syncytial virus. J Med Virol 72:688-694. http://dx.doi.org/10.1002/jmv.20046.
35. Connors M, Kulkarni AB, Collins PL, Firestone CY, Holmes KL, Morse III HC, Murphy BR. 1992. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSVM2protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 66:1277-1281.
36. Karron RA, Buchholz UJ, Collins PL. 2013. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372:259-284. http: //dx.doi.org/10.1007/978-3-642-38919-1_13.
37. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
38. Loomis RJ, Johnson PR. 2013. Gene-based vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol 372:307-324. http: //dx.doi.org/10.1007/978-3-642-38919-1_15.
39. Lawlor HA, Schickli JH, Tang RS. 2013. A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity. J Gen Virol 94:2627-2635. http://dx.doi.org/10.1099/vir.0 .055368-0.
40. Gao F, Li Y, Decker J, Peyerl F, Bibollet Ruche F, Rodenburg C, Chen Y, Shaw D, Allen S, Musonda R, Shaw G, Zajac A, Letvin N, Hahn B. 2003. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNAvaccinated mice. AIDS Res Hum Retroviruses 19:817-823. http://dx.doi .org/10.1089/088922203769232610.
41. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, Garcia-Sastre A. 2009. Optimization of human immunodeficiency virus gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol 83:584-597. http://dx.doi.org/10.1128/JVI.01443-08.
42. Ruiz-Arguello MB, Martin D, Wharton SA, Calder LJ, Martin SR, Cano O, Calero M, Garcia-Barreno B, Skehel JJ, Melero JA. 2004. Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J Gen Virol 85:3677-3687. http://dx.doi.org/10.1099/vir.0.80318-0.